Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic

Documenti analoghi

• Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
  di: Ebaa Al Ozairi, et al.
  Pubblicazione: (2025)
• Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
  di: Jason M. Samuels, et al.
  Pubblicazione: (2024)
• Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
  di: Søren Seier, et al.
  Pubblicazione: (2025)
• Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
  di: Alpana P. Shukla, et al.
  Pubblicazione: (2025)
• Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
  di: Lauren Wilson, et al.
  Pubblicazione: (2026)